Q-omics provides the consensus-scored MED6 profile across patient tissues and cancer cell-line models. MED6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MED6 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, MED6 protein abundance shows 27,150 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where MED6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MED6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MED6 survival associations across molecular data types. MED6 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MED6 RNA expression–survival associations across cancer types. High MED6 expression shows unfavorable associations in KIRP, UVM, ACC, HNSC, LIHC and KICH. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MED6 RNA expression.
This table summarizes MED6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for MED6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MED6 shows higher tumor expression in HNSC, KIRP, LIHC, BLCA, KIRC and LUAD. The HNSC box plot shows higher MED6 RNA expression in tumor versus normal tissue (log2 FC = +0.710, t-test p < 0.001).
This table shows molecular features associated with MED6 in patient tissues and cancer cell lines. In patient samples, MED6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MED6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
